Table 3.
The top 10 journals with highest citations per paper per year in lung cancer immunotherapy from 2010 to 2022 a .
| Journals | Paper number | Top paper number | Top paper rate | Total citation | Citation per paper | Citation per paper per year b | Local citation c | IF (2021) |
|---|---|---|---|---|---|---|---|---|
| N Engl J Med | 13 | 12 | 92.31% | 31845 | 2449.62 | 512.22 | 8266 | 176.079 |
| Lancet | 7 | 5 | 71.43% | 9293 | 1327.57 | 290.55 | 2475 | 202.731 |
| Cancer Cell | 3 | 2 | 66.67% | 941 | 313.67 | 114.86 | 536 | 38.585 |
| Nat. Med. | 6 | 2 | 33.33% | 1043 | 173.83 | 87.33 | 913 | 87.241 |
| Lancet Oncol. | 24 | 15 | 62.50% | 7948 | 331.17 | 80.08 | 2218 | 54.433 |
| Cancer Discov. | 6 | 3 | 50.00% | 1598 | 266.33 | 70.19 | 709 | 38.272 |
| J Clin Oncol | 29 | 16 | 55.17% | 6926 | 238.83 | 66.69 | 5272 | 50.717 |
| Lancet Resp. Med. | 5 | 1 | 20.00% | 706 | 141.20 | 53.74 | 140 | 102.642 |
| JAMA Oncol. | 24 | 9 | 37.50% | 4118 | 171.58 | 52.09 | 1399 | 33.006 |
| Ann. Oncol. | 40 | 8 | 20.00% | 4668 | 116.70 | 33.38 | 2744 | 51.769 |
a
Only journals with more than one paper were included.
b
Papers published in 2022 were not included for calculating citation per paper per year.
c
Citation number in the current dataset (papers in lung cancer immunotherapy from 2010 to 2022).